A monthly audio round-up detailing the contents of the latest issue of DTB. For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page - https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast...
https://dtbbmj.podbean.com
episode 156: July 2023: Whither evidence, COI in guidelines, isotretinoin safety, SGLT2 inhibitors and Utrogestan shortage
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the July 2023 issue of DTB. They discuss evidence-based medicine, access to evidence and increasing use of press releases and social media to present evidence (https://dtb.bmj.com/content/61/7/98). They talk about the safety of isotretinoin (https://dtb.bmj.com/content/61/7/99) and review a study that assessed the accuracy of conflict of interest statements in clinical guidelines (https://dtb.bmj.com/content/61/7/100). The main review article explores the evidence for cardiac and renal effects of SGLT2 inhibitors (https://dtb.bmj.com/content/61/7/103). They begin by discussing the impact of the shortage of Utrogestan.